An article likely to inform clinical practice selected by Dynamed Editorial Team

Liraglutide May Improve Glycemic Control in Patients with Type 2 Diabetes on High-Dose Insulin Therapy

Reference - JAMA Intern Med 2016 Jun 6 early online (level 3 [lacking direct] evidence)

  • Management of patients with type 2 diabetes who have inadequate glycemic control despite treatment regimens including high-dose insulin therapy is a difficult clinical challenge.
  • The addition of liraglutide, a glucagon-like peptide 1 receptor agonist, to high dose insulin regimens reduced HbA1c levels by a mean of 0.9% in 74 patients with inadequately controlled type 2 diabetes.
  • Patients given liraglitude should have close monitoring of insulin levels and adjustment during medication initiation due to an increased risk of hypoglycemia. 

Bookmark and Share